- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00812435
Eptifibatide and ST Segment Resolution Following Primary PCI (ESTEEM)
Study Overview
Detailed Description
The aim of this study is to evaluate the effectiveness and safety of adjunctive eptifibatide during primary PCI in patients presenting to the catheterization laboratory within 12 hours of symptom onset. The primary objective of this randomized clinical trial is to examine the safety and effectiveness of the addition of eptifibatide therapy immediately prior to or at the time of PCI in patients presenting with a STEMI for primary PCI who have not received up-front glycoprotein IIb/IIIa inhibitor therapy. The secondary objective of this clinical trial is to assess effectiveness of adjunct eptifibatide therapy with respect to the following endpoints:
- Complete ST resolution (defined above) at 90 and 180 minutes post primary PCI
- TIMI flow at the end of the PCI (as reported by the investigator at the end of the procedure)
- MACE evaluation at discharge and 30 days post PCI (MACE defined as: death, reinfarction, and need for urgent ischemia-driven target vessel revascularization)
- Stent thrombosis at discharge and 30 days
- Major Bleed (Major Bleed defined as: TIMI Major Bleeding)
- Minor Bleed (Minor Bleed defined as: TIMI Minor Bleeding)
- ST segment resolution at 60, 90 and 180 minutes based on the additional measure in the Schroder's Index:
- Partial resolution defined as 30-70% ST-segment resolution, and
- No resolution defined as <30% ST-segment resolution.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients >18 years old
- Patients with acute myocardial infarction whose symptom onset is within 12 hours of presentation
- ST-segment elevation 1 mm in 2 contiguous limb leads or 2 mm in 2 contiguous precordial leads
- Patients eligible for PCI
- Target lesion(s) in a native vessel
- Target lesion stenosis >50% by angiography (visual estimate)
- Patients who are amenable to participating in study procedures and follow-up
- Patient or legal guardian has been informed and agrees to provide approved written informed consent and data privacy authorization
Exclusion Criteria:
- Patients with cardiogenic shock (SBP<80 mmHg for >30 minutes or requiring pressors or IABP due to hypotension)
- Patients with cardiac arrest at any point prior to intervention (within the preceeding 24 hours)
- Patients on chronic warfarin (Coumadin) therapy
- Patients with known bleeding diathesis or active bleeding at the time of presentation to the catheterization laboratory
- Patients with known bleeding diathesis or active bleeding within prior 3 months
- Patients who receive thrombolytic therapy or glycoprotein IIb/IIIa inhibitors prior to PCI (within the preceding 8 hours)
- Patients with a platelet count <100,000 cells/mm3 within the preceeding 7 days
- Patients with known allergies to aspirin, clopidogrel bisulfate (Plavix), heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors or intravenous contrast dye that cannot be medically managed
- Patients with major surgery within the past 6 months or scheduled surgery within 6 weeks
- Patients with significant unprotected left main disease (stenosis >60%) or with multivessel coronary disease that will require emergent coronary artery bypass surgery
- Patients with TIA or CVA within the past 30 days or any history of hemorrhagic stroke
- Patients who have undergone PCI within the preceding 30 days prior to enrollment
- Patients with known impaired renal function
- Patient is know to be pregnant or lactating
- Patients with active participation in another device or drug study
- Patients with comorbidities conferring a life expectancy of less than a year
- Patients with left bundle branch block
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eptifibatide
PCI with administration of eptifibatide
|
Patients will be randomized to eptifibatide or no eptifibatide.
If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint will be complete ST resolution 60 minutes following primary PCI where complete ST resolution is defined as ≥70% ST resolution compared to the qualifying ECG.
Time Frame: In patient hopsitalization
|
In patient hopsitalization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete ST resolution (defined above) at 90 and 180 minutes following primary PCI; TIMI flow at the end of the PCI; and MACE evaluation at discharge and 30 days post PCI
Time Frame: In-patient hospitalization and 30 days post discharge
|
In-patient hospitalization and 30 days post discharge
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ron Waksman, MD, MedStar Health Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESTEEM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom